Fundraising Fox
Numab
Founded 2011 · 75 employees on LinkedIn · 8 known investors
Find your way into Numab
Each arrow is one introduction. Sign up to fill in the first one.
Ask Dominik Escher to introduce you to David Urech
You →Dominik · together at Swiss Biotech Association →David
Sign up to find every way you can get introduced to Numab
- Your email: who you already know at Numab, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Numab team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
Founders & leadership
Numab was founded in 2011 by David Urech.
Investors · 8
How we know: HBM Healthcare Investments's portfolio page · Not right? Tell us
How we know: HBM Partners's portfolio page · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: a partner's Signal profile · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountseries C roundMay 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Frequently asked questions
- What does Numab do?
- Numab develops multispecific antibody-based therapeutics using its proprietary λ-Cap and MATCH discovery and engineering platforms, aiming to improve on first-generation antibody therapies in potency, stability, effect duration, and safety. It maintains its own drug pipeline targeting clinically validated pathways and works with pharma and biotech partners on discovery and development.
- Who founded Numab?
- Numab was founded by David Urech in 2011.
- Who are Numab's investors?
- Numab's investors include Eisai Innovation, Inc., HBM Healthcare Investments, HBM Partners, Biotechnology Value Fund, BlackRock, Forbion, Novo Holdings, RTW Investments L.P..